Senolytic Combination Strategies for Extending Functional Healthspan

Abstract

Accumulating evidence implicates cellular senescence as a key driver of aging and age-related diseases. Senolytic agents, which selectively eliminate senescent cells, are advancing as promising interventions to extend functional healthspan. However, monotherapies may be limited by incomplete clearance and compensatory mechanisms. Recent research explores combination senolytic strategies pairing agents with complementary mechanisms or adjunctive therapies to synergistically reduce senescent cell burden and ameliorate tissue dysfunction. This review synthesizes current scientific findings, elucidates underlying mechanisms, discusses clinical implications, and highlights emerging guidelines for senolytic combination therapies aimed at optimizing healthspan extension in older adults.

Introduction

Cellular senescence is a fundamental biological process characterized by irreversible cell cycle arrest, resistance to apoptosis, and a pro-inflammatory secretory phenotype. While serving as a tumor-suppressive mechanism, the accumulation of senescent cells contributes to tissue dysfunction, chronic inflammation, and the pathogenesis of multiple age-related diseases. Senolytic agents, designed to selectively target and eliminate these cells, have shown preclinical efficacy in improving organ function, delaying disease onset, and extending healthy lifespan. Combination senolytic strategies aim to overcome limitations of single agents, address cellular heterogeneity, and enhance therapeutic outcomes. This article provides a comprehensive overview of the scientific rationale, clinical evidence, and practical applications of senolytic combination therapies in extending functional healthspan.

Epidemiology / Disease Burden

The demographic shift toward an aging global population has resulted in a surge of age-related chronic diseases, including cardiovascular disease, osteoarthritis, neurodegeneration, and metabolic syndrome. The disease burden associated with functional decline and frailty poses significant challenges for healthcare systems. Evidence from longitudinal cohort studies demonstrates that senescent cell burden increases exponentially with age, correlating with multimorbidity and reduced physical resilience. Interventions targeting senescence are thus poised to address a major unmet need in geriatric medicine by reducing the prevalence and severity of disabling conditions that impair quality of life.

Pathophysiology

Senescent cells accumulate due to various stressors, such as telomere attrition, DNA damage, oncogenic signaling, and mitochondrial dysfunction. These cells adopt a senescence-associated secretory phenotype (SASP), releasing pro-inflammatory cytokines, chemokines, growth factors, and proteases that propagate tissue inflammation and remodeling. The SASP contributes to stem cell exhaustion, extracellular matrix degradation, and immune system dysregulation. Monotherapy with senolytics often targets one anti-apoptotic pathway (e.g., BCL-2 family inhibition by navitoclax), but compensatory survival pathways and cellular heterogeneity can limit efficacy. Combination approaches seek to broaden the mechanistic scope, enhancing senescent cell clearance across diverse tissues and stress contexts.

Risk Factors

Risk factors for accelerated senescent cell accumulation include advanced age, genetic predispositions, obesity, chronic infections, exposure to environmental toxins, and underlying chronic diseases. Iatrogenic factors, such as chemotherapy and radiation, can also induce premature senescence in non-malignant tissues. Identifying patients at high risk for senescent cell burden is essential for targeted therapeutic strategies, particularly in the context of secondary prevention of age-related multimorbidity.

Clinical Features

While senescent cells are not directly observable in standard clinical practice, their presence is inferred from the manifestation of age-related functional decline: sarcopenia, frailty, cognitive impairment, impaired wound healing, and decreased organ reserve. Biomarkers such as increased circulating SASP components (e.g., IL-6, PAI-1), elevated senescence-associated β-galactosidase activity, and expression of p16^INK4a have been used in research settings to quantify senescence burden and monitor response to therapy.

Diagnosis

Diagnosis of senescent cell burden currently relies on a combination of tissue biopsies, molecular markers, and imaging techniques in research contexts. Translational efforts are underway to develop minimally invasive liquid biopsy assays for senescence biomarkers. Functional assessments, such as grip strength, gait speed, and frailty indices, serve as surrogate clinical endpoints in interventional studies evaluating senolytic strategies.

Treatment & Management

Senolytic agents in current clinical development include dasatinib (a tyrosine kinase inhibitor), quercetin (a flavonoid with anti-apoptotic effects), navitoclax (a BCL-2 family inhibitor), and fisetin (a plant polyphenol). Combination strategies typically pair agents with distinct molecular targets, such as dasatinib plus quercetin (D+Q), to optimize senescent cell clearance across tissues. Adjunctive therapies, including immune modulators and SASP inhibitors, are being investigated to further enhance efficacy and minimize inflammatory sequelae.

Recent Advances / Emerging Therapies

Recent preclinical studies demonstrate that combination senolytic regimens yield superior reductions in senescent cell burden and greater improvements in tissue regeneration and function compared to monotherapy. For example, D+Q has been shown to alleviate physical dysfunction in aged mice and improve clinical outcomes in pilot studies of idiopathic pulmonary fibrosis and diabetic kidney disease. Novel agents targeting alternative pathways (e.g., FOXO4-DRI peptides, BET inhibitors) are being trialed in conjunction with established senolytics. Additionally, intermittent dosing regimens are under investigation to minimize toxicity while preserving efficacy.

Guideline Recommendations

As of 2024, formal clinical guidelines on senolytic combination therapy remain in development. However, expert consensus recommends that clinical use be restricted to controlled research protocols, given limited long-term safety data and the potential for off-target effects. Eligibility criteria for future clinical application should include documented functional decline, elevated senescence biomarkers, and careful risk–benefit assessment. Ongoing large-scale randomized trials are expected to inform evidence-based guidelines and dosing strategies in the near future.

Conclusion

Senolytic combination strategies represent a promising frontier in geriatric medicine, with the potential to extend functional healthspan and mitigate the burden of age-related diseases. By leveraging complementary mechanisms of action and targeting cellular heterogeneity, these regimens offer improved efficacy over single-agent approaches. Continued translational research, robust clinical trials, and the development of practical guidelines will be essential to realize the full potential of senolytic therapies for healthy aging in clinical practice.